Genecast
PrivateLast Round
Series E
Oct 27, 2020
Est. Valuation
$779.3M
Total Funding Raised
$638.29M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Genecast is a biotechnology company that develops solutions for non-invasive diagnosis and monitoring of cancer.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Precision Medicine, Medical Devices, Clinical Trials, Healthcare Analytics
Business Model
B2B
Customer Profile
Services & Consulting, Hardware Sales, Subscription SaaS
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Genecast Comparables
Compare Genecast with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| HaploX | 89% | |
| Burning Rock | 89% | |
| New Genetron Holding Limited | 88% |
For institutional investors. Book with your work email.
Genecast Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series E | Oct 27, 2020 | ||||
| Corporate Funding | Oct 19, 2020 | ||||
| Corporate Funding | Jan 6, 2020 | ||||
| Series D | Oct 30, 2019 | ||||
| Series C | Feb 11, 2018 | ||||
Corporate Funding | Nov 23, 2017 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Genecast Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| China Chengtong Fund Management Co., Ltd. | Series E |
| Loyal Valley Capital | Series C |
| CCIC Capital | Corporate Funding, Series D |
| Shenzhen Sangel Venture Capital | Corporate Funding, Angel |
| Hillhouse Investment | Series E |
| Co-Win Ventures | Series D |
| Huasheng Capital | Series E |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 28, 2026
Grew 33% QoQ, from 27 to 36 employees.
- Jul 18, 2026
Grew 40% QoQ, from 25 to 35 employees.
For institutional investors. Book with your work email.
Genecast Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Genecast's valuation, stock price, and market status.
Is Genecast a public or private company?
Genecast is a private company.
What is the current stock price of Genecast?
Genecast is a private company, so its shares have no public market price. Caplight tracks Genecast's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Genecast worth (valuation)?
Genecast's valuation is estimated at $779.3M based on funding round data.
Can I buy Genecast stock?
Genecast shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Genecast's last funding round?
Genecast's most recent funding round was Series E on October 27, 2020.
Who are the main investors in Genecast?
Key investors in Genecast include China Chengtong Fund Management Co., Ltd., Loyal Valley Capital, CCIC Capital, Northern Light Venture Capital, CITIC Private Equity Funds Management.
Will Genecast IPO soon?
No public IPO plans have been announced for Genecast.
How can I track Genecast secondary market activity?
Caplight tracks bids, offers, and trades in Genecast's shares on secondary markets.